 |
allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2) |
|---|---|
| Trade Name | |
| Orphan Indication | Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neuropenia, thrombocytopenia, lymphopenia, and anemia) |
| USA Market Approval | USA |
| USA Designation Date | 2010-12-02 00:00:00 |
| Sponsor | Fate Therapeutics, Inc.;3535 General Atomics Court;San Diego, California, 92121 |
